Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftolozane-tazobactam vs Standard of Care in Febrile Neutropenia
NCT03485950Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2018
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ceftolozane + tazobactam in febrile neutropenia (FN), sponsored by University of Texas MD Anderson Cancer Center. Started May 2018; status: completed.
02
Drugs
ceftolozane + tazobactam
03
Conditions
febrile neutropenia (FN)
Beyond the preview
Go deeper on NCT03485950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03485950.